Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of “Moderate Buy” from Brokerages

Septerna, Inc. (NASDAQ:SEPN) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $52.4444.

A number of research firms have recently commented on SEPN. Stifel Nicolaus set a $49.00 price target on Septerna in a report on Tuesday, August 11th. JonesTrading lifted their target price on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. boosted their target price on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th.

Insiders Place Their Bets

In related news, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $7,665,196. This trade represents a 12.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Samira Shaikhly sold 2,178 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 61,030 shares of company stock valued at $2,329,666. 5.80% of the stock is currently owned by insiders.

Institutional Trading of Septerna

Hedge funds and other institutional investors have recently made changes to their positions in the company. Woodline Partners LP increased its stake in shares of Septerna by 94.2% in the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares during the period. Rhumbline Advisers boosted its position in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after buying an additional 3,323 shares during the period. Geode Capital Management LLC boosted its position in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after buying an additional 78,316 shares during the period. JPMorgan Chase & Co. grew its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC bought a new stake in Septerna during the 2nd quarter worth approximately $133,000.

Septerna Trading Down 3.9%

NASDAQ SEPN opened at $38.91 on Friday. The firm’s 50 day simple moving average is $37.29 and its 200 day simple moving average is $30.81. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -72.06 and a beta of 2.29. Septerna has a 1 year low of $11.70 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. The business had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. On average, equities research analysts forecast that Septerna will post -1.41 earnings per share for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.